Sastasundar Ventures Ltd banner

Sastasundar Ventures Ltd
NSE:SASTASUNDR

Watchlist Manager
Sastasundar Ventures Ltd Logo
Sastasundar Ventures Ltd
NSE:SASTASUNDR
Watchlist
Price: 281.05 INR -1.59% Market Closed
Market Cap: ₹8.9B

Sastasundar Ventures Ltd
Investor Relations

Sastasundar Ventures Ltd. distributes health care and pharmaceutical products. The company is headquartered in Kolkata, West Bengal. The company went IPO on 2010-10-05. The firm's segments include Financial Services and Healthcare Network. The Financial Services segment consists of financing of loans and investment in shares and securities, financial consultancy, professional fees, wealth management, financial planning, distribution and related services. The Healthcare Network segment includes activities for pathology, food processing and marketing of healthcare and over the counter (OTC) products through e-commerce portals, such as www. sastasundar.com, www. retailershakti.com and diagnostic services, which consist of pathological / radiological investigations. The company provides solutions to a range of healthcare needs from preventive care to diagnostics to medicine procurement to doctor consultation. DNAVITA is its health supplement and YANA Diet Clinic is its online diet clinic.

Show more
Loading
SASTASUNDR
BSE Sensex 30
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2026
Call Date
Feb 9, 2026
AI Summary
Q3 2026

Revenue Growth: Sastasundar Ventures reported Q3 revenue of INR 341 crores, up 22% year-on-year and 11% quarter-on-quarter, with 9-month revenue at INR 928 crores, up 15% YoY.

Profitability Improvement: Gross margin improved to 7.6% in Q3 (from 6% YoY). EBITDA losses narrowed significantly, and EBIT turned positive at INR 1 crore versus a loss of INR 37 crores last year.

Guidance Reaffirmed: Management remains confident of hitting guidance, with RetailerShakti targeting EBITDA breakeven by Q4 FY26 and Sastasundar B2C aiming for contribution margin positive in FY27.

JITO Brand Launched: The company launched its JITO generic-generic brand, expecting it to contribute 2% of revenue in the next year and reach 10% in 3–4 years.

Strong Balance Sheet: The company reported INR 500 crores in treasury funds and positive cash flow, with investments in technology funded by treasury income.

Capital Efficiency: Management highlighted their capital-light model, minimal working capital needs, and no credit offered to retailers as key differentiators.

Key Financials
Revenue
INR 341 crores
Revenue (9 months)
INR 928 crores
Gross Margin
7.6% (Q3)
Gross Margin (9 months)
7.5%
EBITDA
negative INR 14 crores
EBIT
INR 1 crores
PAT (9 months)
INR 11 crores
Treasury (Cash on Books)
INR 500 crores (total); INR 400 crores at Sastasundar Healthbuddy
Healthbuddy Count
293
Other Earnings Calls

Management

Mr. Banwari Lal Mittal
Chairman, MD & CEO
No Bio Available
Ms. Manisha Sethia
Chief Financial Officer
No Bio Available
Mr. Pratap Singh
Company Secretary & Compliance Officer
No Bio Available
Subir Basu
Manager of Accounts
No Bio Available

Contacts

Address
WEST BENGAL
Kolkata
Azimganj House, 2nd Floor,, 7, Camac Street,
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett